Adjunctive effect of intravitreal bevacizumab prior to lens-sparing vitrectomy in aggressive posterior retinopathy of prematurity: a case report

Sun, Hae; Choi, Kyung; Lee, Sung
September 2012
Japanese Journal of Ophthalmology;Sep2012, Vol. 56 Issue 5, p476
Academic Journal
Background: Intravitreal injection of bevacizumab in retinopathy of prematurity has shown satisfactory results without any systemic complications. However, increased fibrosis and tissue contraction are reported as adverse effects in some cases. Case: A premature girl, born at 29 weeks + 4 days of gestation, had bilateral aggressive posterior retinopathy of prematurity (APROP) on her first screening at 3 weeks of age. She received extensive, near confluent, laser ablation of the avascular retina and off-label intravitreal bevacizumab (0.75 mg) injection OU. The right eye showed a slight regression, but a localized tractional membrane was noted OS. After another intravitreal bevacizumab injection in each eye, the left eye underwent lens-sparing vitrectomy (LSV) because of contraction of the proliferative membrane leading to a dome-shaped tractional retinal detachment (TRD). Observations: At 6-week follow-up, the left eye showed complete retinal reattachment. Both eyes showed prompt resolution of vascular engorgement with anterior progression of the peripheral retinal vasculature. Conclusions: Intravitreal bevacizumab is safe and effective as a treatment of APROP. In some cases tissue contraction may occur, but because TRD is localized to the posterior pole, effective LSV can be performed.


Related Articles

  • Functional and anatomical outcomes after primary lens-sparing pars plana vitrectomy for Stage 4 retinopathy of prematurity. Bhende, Pramod; Gopal, Lingam; Sharma, Tarun; Verma, Aditya; Biswas, Rupak Kanti // Indian Journal of Ophthalmology;Sep2009, Vol. 57 Issue 4, p267 

    Background: While lens-sacrificing vitrectomy is the standard approach to manage Stage 5 retinopathy of prematurity (ROP), scleral buckling has been used to manage some cases of Stage 4. Lens-sparing vitrectomy was popularized by Maguire and Trese in selected cases of Stage 4 disease. Purpose:...

  • Delayed onset atypical vitreoretinal traction band formation after an intravitreal injection of bevacizumab in stage 3 retinopathy of prematurity. Lee, B J; Kim, J H; Heo, H; Yu, Y S // Eye;Jul2012, Vol. 26 Issue 7, p903 

    PurposeTo report a series of patients who presented with an atypical retinal traction band, which was developed after an intravitreal injection of bevacizumab for stage 3 retinopathy of prematurity (ROP).MethodsWe retrospectively reviewed the medical record of three patients (five eyes) who had...

  • Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Kusaka, S.; Shima, C.; Wada, K.; Arahori, H.; Shimojyo, H.; Sato, I.; Fujikado, T. // British Journal of Ophthalmology;Nov2008, Vol. 92 Issue 11, p1450 

    Aim: The aim of the study was to evaluate the short-term efficacy of intravitreal injections of bevacizumab for severe retinopathy of prematurity (ROP). Methods: A retrospective chart review was conducted of 23 consecutive eyes (stage 3, three eyes; 4A, 18 eyes; 4B, two eyes) of 14 patients with...

  • Lens-sparing vitrectomy may halt stage 4A ROP. Guttman, Cheryl // Ophthalmology Times;8/1/2001, Vol. 26 Issue 15, p1 

    Reports that lens-sparing vitrectomy for tractional stage 4A retinopathy of prematurity (ROP) retinal detachment appears to be an effective approach for interrupting to more advanced stages of ROP. Visual outcome after the process; Alternative to scleral buckling.

  • Bevacizumab.  // Reactions Weekly;9/18/2010, Issue 1319, p11 

    The article describes the case of a male neonate who developed choroidal rupture after he received combined laser ablation treatment and intravitreal bevacizumab for aggressive posterior retinopathy of prematurity (ROP).

  • Avastin May Offer ROP Treatment.  // Review of Ophthalmology;Mar2011, Vol. 18 Issue 3, p10 

    The article reviews the article "Avastin May Offer ROP Treatment" which appeared in the "New England Journal of Medicine" in February 17, 2011.

  • 25 gauge vitrectomy under topical anesthesia: a pilot study. Raju, Biju; Raju, N. S. D.; Raju, Anju S. // Indian Journal of Ophthalmology;Sep2006, Vol. 54 Issue 3, p185 

    Aims: To evaluate the safety and efficacy of transconjunctival 25 gauge vitrectomy under topical anesthesia.Settings and Design: A pilot study of consecutive cases which underwent 25 gauge vitrectomy under topical anesthesia.Materials and Methods: Seven...

  • 23 Gauge: The Further Evolution of Vitrectomy. Tewari, Asheesh; Shah, Gaurav K. // Review of Ophthalmology;Aug2006, Vol. 13 Issue 8, p76 

    The article discusses the principles and techniques of the 23 gauge transconjunctival sutureless vitrectomy in vitreoretinal surgery. Twenty-three gauge transconjunctival sutureless vitrectomy allows greater eye rotation and the ability to perform a more complete vitrectomy, by providing more...

  • Small-Gauge Vitrectomy: The Future Is Now. Roe, Richard H.; Fu, Arthur D. // Review of Ophthalmology;Jun2007 Part 1 of 2, Vol. 14 Issue 6, p86 

    The article focuses on the significance of small-gauge vitrectomy surgery, an endoscopy-based procedure, in the U.S. The procedure involves the use of sutureless infusion cannulas and larger incisions for instruments in retinal pathology. Robert Machemer, the inventor of the procedure, believed...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics